Drug Guidance for Subsidy 02/01/2024 Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions The Ministry of Health’s Drug Advisory Committee has reviewed all available treatments for cancer to... See all × 02/01/2024 Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions The Ministry of Health’s Drug Advisory Committee has reviewed all available treatments for cancer to update the MOH List of Subsidised Drugs in line with local clinical practice and medical advancements. As part of this review, Technology Guidances have been prepared which describe the subsidy recommendations for many cancer drugs for specific clinical conditions. The remaining treatments which have been considered by the Committee are included in this document. RBased on the available evidence, the Ministry of Health’s Drug Advisory Committee has recommended: Abemaciclib 50 mg, 100 mg and 150 mg tablets; Abiraterone acetate 250 mg tablets; Afatinib 20 mg, 30 mg and 40 mg tablets; Alectinib 150 mg capsule; Anagrelide 0.5 mg capsule; Atezolizumab 840 mg/14 mL and 1200 mg/20 mL concentrate for solution for infusion; Avelumab 200 mg/10 mL concentrate for solution for infusion; Axitinib 1 mg and 5 mg tablets; Azacitidine 100 mg injection; Bendamustine 25 mg and 100 mg concentrate for infusion; Bicalutamide 50 mg tablet; Bortezomib 3.5 mg injection; Brentuximab vedotin 50 mg powder for concentrate for solution for infusion; Brigatinib 30 mg, 90 mg and 180 mg tablets; Cabozantinib 20 mg, 40 mg and 60 mg tablets; Ceritinib 150 mg capsule; Cetuximab 100 mg/20 mL solution for infusion; Cisplatin 100 mg/100 mL concentrate for infusion; Cyproterone 50 mg tablet; Dabrafenib 50 mg and 75 mg capsules; Dasatinib 20 mg, 50 mg and 70 mg tablets; Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion; Epirubicin 50 mg/25 mL injection; Eribulin mesylate 1 mg/2 mL solution for injection; Erlotinib 100 mg and 150 mg tablets; Exemestane 25 mg tablet; Fludarabine phosphate 50 mg injection; Fulvestrant 250 mg/5 mL solution for injection; Gefitinib 250 mg tablet; Gilteritinib fumarate 40 mg tablet; Goserelin 3.6 mg and 10.8 mg depot injections; Imatinib 100 mg and 400 mg tablets; Ipilimumab 50 mg/10 mL concentrate for solution for infusion; Lapatinib 250 mg tablet; Lenalidomide 5 mg, 10 mg, 15 mg and 25 mg capsules; Leuprorelin acetate 3.75 mg and 11.25 mg depot injections; Lorlatinib 25 mg and 100 mg tablets; Megestrol 40 mg and 160 mg capsules; Midostaurin 25 mg capsule; Nilotinib 50 mg, 150 mg and 200 mg capsules; Nivolumab 40 mg/4 mL and 100 mg/10 mL concentrate for solution for infusion; Obinutuzumab 1000 mg/40 mL concentrate for solution for infusion; Olaparib 100 mg and 150 mg tablets; Oxaliplatin 200 mg/40 mL concentrate for infusion; Paclitaxel-albumin bound nanoparticles 100 mg injectable suspension; Palbociclib 75 mg, 100 mg and 125 mg capsules/tablets; Pazopanib 200 mg and 400 mg tablets; Pegylated liposomal doxorubicin 20 mg concentrate for infusion; Pembrolizumab 100 mg/4 mL solution for infusion; Pemetrexed 100 mg and 500 mg injections; Ponatinib 15 mg tablet; Ribociclib 200 mg tablet; Ruxolitinib 5 mg, 15 mg and 20 mg tablets; Somatropin 5 mg/1.5 mL and 10 mg/1.5 mL prefilled pens; Somatropin 4 mg and 5.3 mg/mL powder and solvent for solution for injection; Somatropin 5.83 mg/mL and 8 mg/mL solution for injection; Trametinib 0.5 mg and 2 mg tablets; and Vinorelbine 50 mg/5 mL injection for inclusion on the MOH Standard Drug List (SDL) or Medication Assistance Fund (MAF) in line with their registered indications or specific clinical criteria for treating cancer, in view of clinical need, and acceptable clinical and cost effectiveness. NRDrugs that have not been recommended for subsidy are listed in the Annex. For all drugs, the clinical indications, subsidy class, subsidy implementation dates (if applicable), and MediShield Life claim limits are provided in the Annex. 02/01/2024 Review of cancer drugs for previously treated advanced hepatocellular carcinoma The Ministry of Health’s Drug Advisory Committee has recommended: Cabozantinib 20 mg, 40 mg and 60 ... See all × 02/01/2024 Review of cancer drugs for previously treated advanced hepatocellular carcinoma The Ministry of Health’s Drug Advisory Committee has recommended: Cabozantinib 20 mg, 40 mg and 60 mg tablets; and Regorafenib 40 mg tablet for treating advanced unresectable hepatocellular carcinoma in patients with disease progression after one or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. Funding status RRegorafenib 40 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 4 January 2022. RCabozantinib 20 mg, 40 mg and 60 mg tablets are recommended for inclusion on the MAF for the abovementioned indication with effect from 1 September 2022. NRMAF assistance does not apply to any formulations or strengths of ramucirumab, pembrolizumab, nivolumab and ipilimumab when used for previously treated advanced hepatocellular carcinoma. Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex. 02/01/2024 Review of cancer drugs for treating advanced urothelial carcinoma The Ministry of Health’s Drug Advisory Committee has recommended: Avelumab 200 mg/10 mL concentrat... See all × 02/01/2024 Review of cancer drugs for treating advanced urothelial carcinoma The Ministry of Health’s Drug Advisory Committee has recommended: Avelumab 200 mg/10 mL concentrate for solution for infusion; and Pembrolizumab 100 mg/4 mL solution for infusion for treating advanced urothelial carcinoma (UC) in line with specific clinical criteria. Funding status RAvelumab 200 mg/10 mL concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for maintenance treatment of locally advanced or metastatic UC that has not progressed with first-line platinum-based chemotherapy when used in line with the treatment regimen outlined in the Annex. RPembrolizumab 100 mg/4 mL solution for infusion is recommended for inclusion on the MAF for treating patients with locally advanced or metastatic UC after receiving platinum-based chemotherapy in line with the following criteria: Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for locally advanced or metastatic UC; and Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. Pembrolizumab retreatment is allowed at time of progression for up to 1 additional year if the initial treatment was stopped for reasons other than disease progression. RMAF assistance for the abovementioned treatments will be implemented from 1 September 2022. NRMAF assistance does not apply to pembrolizumab when used for patients with untreated PD-L1-positive UC who are unable to receive cisplatin-based chemotherapy, or erdafitinib when used for treating UC with FGFR3 genetic alterations. Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex. 02/01/2024 Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended pembrolizumab for inclusion o... See all × 02/01/2024 Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended pembrolizumab for inclusion on the MOH List of Subsidised Drugs, when used in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in patients whose tumours express programmed death-ligand 1 with a combined positive score greater than or equal to 1. The decision was based on the uncertain extent of clinical benefit and unfavourable cost-effectiveness of pembrolizumab at the price proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for pembrolizumab are provided in the Annex. 02/01/2024 Pembrolizumab for treating high-risk early-stage triple-negative breast cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended pembrolizumab for inclusion o... See all × 02/01/2024 Pembrolizumab for treating high-risk early-stage triple-negative breast cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended pembrolizumab for inclusion on the MOH List of Subsidised Drugs, when used in combination with chemotherapy as neoadjuvant treatment and then continued as adjuvant monotherapy after surgery, for treating high-risk, early-stage, triple-negative breast cancer. The decision was based on the uncertain extent of clinical benefit and unfavourable cost-effectiveness of pembrolizumab at the price proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for pembrolizumab are provided in the Annex. 02/01/2024 Pembrolizumab for the adjuvant treatment of renal cell carcinoma NRThe Ministry of Health’s Drug Advisory Committee has not recommended pembrolizumab for inclusion o... See all × 02/01/2024 Pembrolizumab for the adjuvant treatment of renal cell carcinoma NRThe Ministry of Health’s Drug Advisory Committee has not recommended pembrolizumab for inclusion on the MOH List of Subsidised Drugs for the adjuvant treatment of renal cell carcinoma in patients who are at increased risk of recurrence following nephrectomy or nephrectomy with resection of metastatic lesions. The decision was based on the uncertain extent of clinical benefit and unfavourable cost-effectiveness of pembrolizumab at the price proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for pembrolizumab are provided in the Annex. 19/12/2022 Immune checkpoint inhibitors and BRAF/MEK inhibitors for treating advanced malignant melanoma The Ministry of Health’s Drug Advisory Committee has recommended: Dabrafenib 50 mg and 75 mg capsul... See all × 19/12/2022 Immune checkpoint inhibitors and BRAF/MEK inhibitors for treating advanced malignant melanoma The Ministry of Health’s Drug Advisory Committee has recommended: Dabrafenib 50 mg and 75 mg capsules and trametinib 0.5 mg and 2 mg tablets; Nivolumab 40 mg/4 mL and 100 mg/10 mL concentrate for solution for infusion; Nivolumab 40 mg/4 mL, 100 mg/10 mL and 240 mg/24 mL concentrate for solution for infusion used in combination with ipilimumab 50 mg/10 mL concentrate for solution for infusion; and Pembrolizumab 100 mg/4 mL solution for infusion for treating advanced malignant melanoma in line with specific clinical criteria. Subsidy status RDabrafenib 50 mg and 75 mg capsules used in combination with trametinib 0.5 mg and 2 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for treating advanced unresectable or metastatic malignant melanoma in patients with a BRAF V600 mutation with effect from 4 January 2022. RNivolumab 40 mg/4 mL and 100 mg/10 mL concentrate for solution for infusion and pembrolizumab 100 mg/4 mL solution for infusion are recommended for inclusion on MAF for: adjuvant treatment of completely resected malignant melanoma with lymph node involvement; and treating advanced unresectable or metastatic malignant melanoma. RNivolumab 40 mg/4 mL, 100 mg/10 mL and 240 mg/24 mL concentrate for solution for infusion used in combination with ipilimumab 50 mg/10 mL concentrate for solution for infusion are recommended for inclusion on MAF for treating advanced unresectable or metastatic malignant melanoma. RMAF assistance for nivolumab, ipilimumab and pembrolizumab will be implemented from 1 September 2022. Treatments should be given in line with the dosing regimens outlined in the Annex. NRMAF assistance does not apply to: dabrafenib 50 mg and 75 mg capsules used in combination with trametinib 0.5 mg and 2 mg tablets for adjuvant treatment of completely resected BRAF V600 mutation positive malignant melanoma with lymph node involvement; and cobimetinib 20 mg and vemurafenib 240 mg tablets. Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex. 19/12/2022 Review of cancer drugs for previously treated advanced gastric cancer The Ministry of Health’s Drug Advisory Committee has recommended: Nivolumab 40 mg/4 mL and 100 mg/1... See all × 19/12/2022 Review of cancer drugs for previously treated advanced gastric cancer The Ministry of Health’s Drug Advisory Committee has recommended: Nivolumab 40 mg/4 mL and 100 mg/10 mL concentrate for solution for infusion for treating patients with unresectable locally advanced or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma after two or more prior systemic therapies in line with the following criteria: Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for unresectable locally advanced or recurrent gastric or GEJ cancer; and Nivolumab should be given as a weight-based dose up to a maximum of 240 mg every two weeks or 480 mg every four weeks. Subsidy status RNivolumab 40 mg/4 mL and 100 mg/10 mL concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 1 September 2022. NRMAF assistance does not apply to any formulations or strengths of pembrolizumab, ramucirumab, regorafenib or trifluridine/tipiracil when used for previously treated advanced gastric cancer. Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.
INTRAVENOUS Select a brand starting with the letter: P PEMBROLIZUMAB SOLUTION FOR INFUSION 25MG/ML [SIN16677P]